Nicole Kimzey
Internal Medicine · Philadelphia, PANPI 1184868101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 751 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 751 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$3K
- GSK$2K
- Boehringer Ingelheim$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lilly USA, LLC$1K
- plus $7K from 26 others
Across 4 payments — averaging $119.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$478
What the payments were for
- Food & beverage$19,23499%
- Education$1561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $3,424 |
| Novo Nordisk | 128 | $3,057 |
| GSK | 48 | $1,792 |
| Boehringer Ingelheim | 51 | $1,300 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $1,279 |
| Lilly USA, LLC | 53 | $1,207 |
| Pfizer | 54 | $1,026 |
| Amgen | 21 | $684 |
| Amarin Pharma, Inc. | 33 | $683 |
| AstraZeneca | 20 | $553 |
| Astellas Pharma US Inc | 20 | $536 |
| Heartflow, Inc. | 7 | $532 |
| Philips North America LLC | 27 | $449 |
| Phathom Pharmaceuticals, Inc. | 3 | $374 |
| Otsuka America Pharmaceutical, Inc. | 3 | $349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $295 |
| Esperion Therapeutics, Inc. | 12 | $274 |
| Vanda Pharmaceuticals Inc. | 6 | $208 |
| Sanofi-aventis U.S. LLC | 7 | $170 |
| Biohaven Pharmaceuticals, Inc. | 8 | $159 |
| Idorsia Pharmaceuticals US Inc | 4 | $155 |
| Novartis | 9 | $146 |
| Avanir Pharmaceuticals, Inc. | 3 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $134 |
| Nestle Healthcare Nutrition Inc. | 7 | $112 |
| Aimmune Therapeutics, Inc. | 5 | $80 |
| Merck | 6 | $80 |
| Arbor Pharmaceuticals, Inc. | 4 | $69 |
| Abbott | 2 | $44 |
| Eisai Inc. | 2 | $42 |
| Verona Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,390 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $58,626 |
| VraylarCariprazine Hcl | 21 | $29,377 |
| TrulicityDulaglutide | 25 | $23,922 |
| EliquisApixaban | 34 | $20,868 |
| EntrestoSacubitril/Valsartan | 15 | $12,716 |
| JardianceEmpagliflozin | 17 | $12,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,656 |
| Butorphanol Tartrate | 55 | $6,802 |
| MyrbetriqMirabegron | 13 | $6,343 |
| FarxigaDapagliflozin Propanediol | 12 | $6,268 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $3,404 |
| Valsartan | 95 | $2,363 |
| Atorvastatin Calcium | 152 | $2,187 |
| Omega-3 Acid Ethyl Esters | 19 | $1,992 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,057 | $58,62662 claims |
| AbbVieVraylar | $3,424 | $29,37721 claims |
| Lilly USA, LLCTrulicity | $1,207 | $23,92225 claims |
| PfizerEliquis | $1,026 | $20,86834 claims |
| NovartisEntresto | $146 | $12,71615 claims |
| Boehringer IngelheimJardiance | $1,300 | $12,33317 claims |
| GSKTrelegy Ellipta | $1,792 | $7,65612 claims |
| Astellas Pharma US IncMyrbetriq | $536 | $6,34313 claims |
| AstraZenecaFarxiga | $553 | $6,26812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.